Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
CAR T cells have revolutionised the treatment of haematological malignancies. Despite this, several obstacles still prohibit their widespread use and efficacy. One of these barriers is the use of autologous T cells as the carrier of the CAR. The individual production of CAR T cells results in large...
Main Authors: | Lauren C. Cutmore, John F. Marshall |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/8/1926 |
Similar Items
-
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
by: Kevin Pan, et al.
Published: (2022-03-01) -
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
by: Erica L. Heipertz, et al.
Published: (2021-12-01) -
CAR-NK cells for cancer immunotherapy: recent advances and future directions
by: Tianye Li, et al.
Published: (2024-02-01) -
Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
by: Alexandre Juillerat, et al.
Published: (2020-06-01) -
CAR‐NK cells from engineered pluripotent stem cells: Off‐the‐shelf therapeutics for all patients
by: Shi‐Jiang Lu, et al.
Published: (2021-11-01)